

Index

A

α -adrenergic blockade, 55
Ablative neurosurgery, 83
Activity scheduling, 61
Acupuncture, 64, 69–71
Alcohol, 7, 13
Alprazolam, 50
Amfebutamone, 52
Amitriptyline, 34
Anhedonia, 13, 17, 18
Anterior cingulate cortex, 68
Anterior cingulotomy, 66
Anticancer agents, 7
Anticholinergics, 7
Antidepressant discontinuation syndrome, 56–57
Antidepressants, 20
Antihypertensive agents, 7
Antiparkinsonian agents, 7
Antipsychotic, 34
Antituberculosis agents, 7
Anxiety, 18
Anxiety disorders, 7
Appetite, 18
 α_2 -presynaptic receptors, 50
Aripiprazole, 81
Atypical antipsychotics, 56, 81
Augmentation, 81
Autoimmune disorders, 14
Automatic negative thoughts, 60
Autonomic instability, 56

B

Baby blues, 13
Barbiturates, 7
Beck Depression Inventory (BDI), 29
Behavior therapy, 61
Behavioral activation, 32
Benzodiazepines, 7
Bereavement, 20
Bipolar disorders, 1
Brain stimulation, 32
Bright light therapy, 32

Bulimia, 13

Bupropion, 12, 51

Bupirone, 81

C

CYP2C9, 46
CYP2C19, 46
CYP3A4, 46
Cancer, 14
Carbamazepine, 52
Cardiovascular disease, 14
Catatonia, 18
Catecholamine, 45
Causes of depression, 5–7
Cerebrovascular accident (CVA), 14
Cheese reaction, 55
Chest X-ray, 24
Children, 11–12
Chlorpromazine, 55
Choosing a specific antidepressant, 37
Chronic major depression, 8
Citalopram, 12
Clomipramine, 52
Clozapine, 47
Cocaine, 19
Cognitive-behavioral therapy (CBT), 12, 32, 59
Cognitive dysfunction, 24
Cognitive impairment, 19
Cognitive model, 6
Cognitive triad, 60
Collaborative empiricism, 60
Combined or combination treatment, 61
Combining drugs, 81
Common medications that may cause symptoms similar to depression, 24
Composite International Diagnostic Interview (CIDI), 9
Consortium for Research in ECT (CORE), 64
Continuation treatment, 30
maintenance, 85

Continuum model, 86
 Coronary artery disease, 14
 Critical decision points, 40
 CYP1A2, 46
 CYP2D6, 46
 Cytochrome (CYP) enzymes, 38

D

Decreased appetite, 18
 Deep brain stimulation (DBS), 64, 68
 Dementia, 14, 19
 Depression
 atypical features, 4
 core symptom, 2
 catatonic features, 4
 children, 11–12
 psychotherapies, 12
 chronic, 2
 comorbid medical conditions, 14
 dysthymia, 3
 in elderly people, 12–13
 melancholic features, 4
 postpartum depression, 9
 psychotic features, 4
 seasonal depression, 9
 seasonal features, 4
 in women, 13
 Desmethylsertraline, 46
 Diagnosis, 17–24
 Diagnostic and Statistical Manual of Mental Disorders, 1
 Dialysis, 56
 Directed self-help/computerized cognitive–behavioral therapy, 32
 Discontinuation reaction, 39
 Disequilibrium symptoms, 57
 Dopamine (DA), 6
 Dose increase, 80
 Dosulepin (dothiepin), 53
 Dothiepin, 53
 Drug–drug interactions, 37
 Drugs of abuse, 19
 DSM-IV/ classification, 1, 2
 Dual diagnosis, 19
 Duloxetine, 12, 48
 Dynamic model, 6

Dysfunctional
 beliefs, 60
 thoughts, 60
 Dysphoria, 17
 Dysthymic disorder (DD), 1

E

Early morning awakening, 18
 Early trauma, 23
 Eating disorders, 7
 Education, 35
 Electric shock feelings, 57
 Electroconvulsive therapy (ECT), 32, 35, 64
 Endocrine disorders, 19
 Environmental factors, 5
 Epidemiology, 8
 EQ-5D, 29
 Erythromycin, 51
 Escitalopram, 34
 Estrogen, 13
 Exercise, 68, 69
 Extrapyramidal symptoms, 57

F

Family medical history, 23
 Fatigue, 18
 Fluoxetine, 11
 Fluvoxamine, 46
 Folic acid, 32
 Food and Drug Administration (FDA), 11
 Frequency, Intensity and Side Effect Rating (FISER) scale, 20

G

Genetic basis of depression, 5
 Genetic markers, 34
 Global Assessment of Functioning (GAF), 29
 Goals of treatment, 27–31
 Grief reactions, 20
 Guilt, 18

H

Hallucinations, 19
 Hamilton Depression Rating Scale (HDRS), 28

High-dose antidepressants, 80
 Hippocampus, 63
 History, 20
 Homework assignments, 61
 Hormones, 7
 Hospital Anxiety and Depression Scale (HADS), 29
 5HT_{1A}-receptors, 45
 5HT₃ receptors, 50
 Human immunodeficiency virus (HIV), 14
 5-hydroxytryptamine (5HT), 45
 Hypericum extracts (St John's wort), 68
 Hypersomnia, 18

I

International Classification of Mental and Behavioral Disorders
 ICD-10, 1
 ICD-10 classification, 2
 ICD-10 system, 1, 2, 18
 Imipramine, 52
 Infectious disorders, 19
 Inflammatory cytokines, 14
 Informed choices, 27, 36
 Insight, 24
 Insomnia, 18
 Interpersonal context, 59
 Interpersonal psychotherapy (IPT), 32, 36, 59
 Interpersonal theory, 6
 Interview, 20–24
 Isocarboxazid, 54

K

Kandel, 5
 Ketoconazole, 51

L

Laboratory
 tests, 24
 examinations, 24
 L-dopa, 54
 Lithium, 47
 Lithium augmentation, 81
 Liver function tests, 24
 L-Tryptophan, 47

M

Maintenance treatment, 30
 Major depressive disorder (MDD), 1
 MAO-A, 55
 MAO-B, 55
 m-Chlorophenylpiperazine, 50
 Medical
 conditions, 19
 illnesses, 24
 Medical history, 23
 Medical Outcomes Study, 29
 Melatonin, 66
 Mental Health legislation, 35
 Mental status (state) examination, 23
 Metabolic disorders, 19
 Methamphetamine, 19
 Milnacipran, 48
 Mini-Mental State Examination (MMSE), 24
 Minor depression, 32
 Mirtazapine, 12
 Model of phases of treatment, 85
 Monoamine hypothesis of depression, 45
 Monoamine oxidase inhibitors, 32
 Montgomery Åsberg Depression Rating Scale (MADRS), 28
 Mood-congruent features, 4
 Mood-congruent psychotic features, 19
 Mood-incongruent features, 4
 Multiple sclerosis, 14
 Mutism, 18
 Myoclonic jerks, 56

N

National Comorbidity Survey, 8
 National Institute for Health and Clinical Excellence (NICE), 41
 Nefazodone, 49
 Neonatal behavioral syndrome, 38
 Neurological disorders, 19
 Next-step treatment, 79
 Nondirective therapy/counseling, 32
 Nonspecific support, 32
 Norepinephrine/noradrenaline (NE), 6
 Norepinephrine reuptake inhibitors, 32

Norfluoxetine, 46
 Nortriptyline, 53
 Number needed to harm (NNH), 11

O

Obsessive-compulsive disorder, 11
 O-Desmethylvenlafaxine, 48
 Olanzapine, 47, 81
 Omega-3-fatty acids (O-3-FA), 32, 68,
 70–71
 Opiates, 47
 Opioids, 7, 19, 54

P

Paraesthesia, 57
 Parkinson's disease, 14
 Paroxetine, 46
 Partial remission, 28
 Past medical history, 23
 Past psychiatric illness, 23
 Patient choice, 78
 Patient examination, 20–24
 Patient Health Questionnaire (PHQ-9),
 29
 Perimenopausal, 13
 Pethidine, 54
 Pharmacodynamic, 46
 Pharmacokinetics, 37
 Phenelzine, 54
 Phentolamine, 55
 Phenylethylamine, 55
 Phenytoin, 52
 Pheochromocytoma, 55
 Phototherapy, 64, 66
 Pindolol augmentation, 81
 Placebo, 31
 Placebo effect, 31
 Postmenopausal, 13
 Postpartum depression, 13
 Post-stroke depression [PSD], 14
 5HT₂, 50
 Prefrontal cortex, 63
 Pregnancy, 13
 Presynaptic nerve terminal, 46
 Prevalence, 8
 Problem-solving therapy, 32
 Prophylactic treatment, 30

Propranolol, 47
 Pseudodementia of depression, 19
 Psychiatric interview, 20
 Psychoanalysis, 63
 Psychoeducation, 64
 Psychomotor
 activity, 18
 changes, 18
 retardation, 18
 Psychotherapy, 5

Q

Quality of life, 28
 Quetiapine, 81
 Quick Inventory of Depressive
 Symptomatology–Self Rated
 (QIDSSR), 20, 29
 QIDS-SR₁₆, 20

R

Rating scales, 28
 Reboxetine, 39, 51
 Receptor antagonists, 32
 Recurrent depression, 77
 Reduced concentration, 18
 Reduced energy, 18
 Relapse/recurrence, 85
 Remission/recovery, 28
 Reserpine, 45
 Residual symptoms, 88
 Response, 28
 Reversible inhibitor of MAO-A (RIMA),
 55
 Risk, 35
 Risperidone, 81
 Role transitions, 60

S

Sad mood, 18
 Schizo-affective disorder, 19
 Schizophrenia, 7, 19
 Seasonal affective disorder (SAD), 19,
 34, 66
 Seasonal depression, 66
 Selective serotonin reuptake inhibitor
 (SSRI), 5
 paroxetine, 12

treatment of depression in young
 people, 11
 Self-esteem, 18
 Self-report measures, 28
 Sequenced Treatment Alternatives to
 Relieve Depression (STAR*D), 8, 19,
 20
 Serotonin (5HT), 6
 Serotonin and norepinephrine reuptake
 inhibitors, 32
 Serotonin syndrome, 56
 Serotonin transporter gene, 5
 Sertraline, 12, 46
 Severe life event, 6
 Sexual function, 49
 Short Form 36 (SF-36), 29
 Side effects, 79
 Sleep, 18
 Social role, 60
 Social support, 60
 Somatic symptoms, 18
 Somatoform disorders, 13
 St John's wort (*Hypericum perforatum*),
 32, 70
 Subcaudate tractotomy, 66
 Subgenual cingulate area, 68
 Substance abuse, 7
 Suicide, 5, 18
 distal risk factors, 17
 proximal risk factors, 17
 Switching treatment, 80
 Synaptic availability, 45

T

Tapering, 57
 T₃ augmentation, 81
 Texas Medication Algorithm Project
 (TMAP), 12

Therapeutic alliance, 35
 Thought disorder, 19
 Thyroid function tests, 24
 Transcranial magnetic stimulation
 (TMS), 64, 66–67
 Tranylcypromine, 54
 Trazodone, 32, 49
 Treatment adherence, 28
 Treatment algorithms, 40
 Treatment nonresponse, 77–83
 Treatment of Adolescents with
 Depression Study (TADS), 12
 Treatment-resistant depression (TRD),
 79
 Treatment-resistant MDDs, 66
 Tricyclic antidepressants, 32
 Tryptophan augmentation, 81
 Tyramin, 55

V

Vagus nerve stimulation (VNS), 64, 67
 Valproate, 52
 Vascular dementia, 14
 Vascular depression, 12
 Venlafaxine, 12, 34

W

Warfarin, 47
 Watchful waiting, 34
 Weight loss?, 18
 Worthlessness, 18